Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells
about
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression managementLiver transplantation: immunosuppression and oncologyBurden of de novo malignancy in the liver transplant recipientStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationHonokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer developmentNovel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal.Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progressionAnti-breast tumor activity of Eclipta extract in-vitro and in-vivo: novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosisMalignancies in a renal transplant population: The St. Michael's Hospital experience.The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.Is murine gammaherpesvirus-68 (MHV-68) a suitable immunotoxicological model for examining immunomodulatory drug-associated viral recrudescence?Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.H2-P, a honokiol derivative, exerts anti-angiogenesis effects via c-MYC signaling pathway in glioblastoma.Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
P2860
Q26772295-3130345C-4F20-4FDB-A7FF-165BD25DBF29Q26827252-9F97038E-EB21-4ECC-96F9-23CA8F8ED08DQ26859216-BC05DAFD-B612-4697-8F97-0B1ACCEC9D90Q27005375-45163F69-FEA3-469E-A27C-4359A2445B31Q33919087-384DADAA-4771-4CFE-997D-4994707D3953Q34009025-7121EF45-DECE-4818-A37E-3FC7015FFD22Q34055699-223A9D8E-EC08-4CF1-9568-FBE7F62E1404Q35221521-819CD723-0D38-4AE0-A21B-6F462DF7555DQ35312808-52A19047-6F8A-46BB-A92D-2ACE273BBC78Q35973628-65673F09-2E5C-4996-AA22-92C8F03A6D81Q36379354-1BDF1A6F-C72C-4C41-AA18-ED1FFCFDF2F0Q36820830-FC4C9425-2304-4619-A87A-BDDCD93CB647Q37112443-FAA225C7-DD9F-43DC-BFB2-0E4C8019774FQ38186778-3BB8F580-30EF-4083-9BC5-C6E8ADFF627DQ42559398-18552EE8-EADC-4356-AA5E-4BED2E444279Q47697715-3067186D-417A-42FE-BE8F-EA2B3414213FQ51273202-420BF2EF-7515-4DB6-BE40-9B1BEC07E9D3Q51560838-7466EF80-AAA5-475F-B9D3-753CB785F217
P2860
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Calcineurin inhibitors activat ...... signals in renal cancer cells
@en
Calcineurin inhibitors activat ...... signals in renal cancer cells.
@nl
type
label
Calcineurin inhibitors activat ...... signals in renal cancer cells
@en
Calcineurin inhibitors activat ...... signals in renal cancer cells.
@nl
prefLabel
Calcineurin inhibitors activat ...... signals in renal cancer cells
@en
Calcineurin inhibitors activat ...... signals in renal cancer cells.
@nl
P2093
P2860
P1433
P1476
Calcineurin inhibitors activat ...... signals in renal cancer cells
@en
P2093
Alan G Contreras
Aninda Basu
Dipak Datta
Evelyn Flynn
Soumitro Pal
P2860
P304
P356
10.1158/0008-5472.CAN-09-1404
P407
P577
2009-11-10T00:00:00Z